Recombinant
RabMAb

Anti-Von Willebrand Factor antibody [EPR12011] (ab174290)

Overview

  • Product name
    Anti-Von Willebrand Factor antibody [EPR12011]
    See all Von Willebrand Factor primary antibodies
  • Description
    Rabbit monoclonal [EPR12011] to Von Willebrand Factor
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WBmore details
    Unsuitable for: ICC/IF,IHC-P or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human Von Willebrand Factor aa 2050-2150 (Cysteine residue). The exact sequence is proprietary.
    Database link: P04275

  • Positive control
    • Human plasma and serum lysates.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab174290 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 309 kDa.
  • Application notes
    Is unsuitable for ICC/IF,IHC-P or IP.
  • Target

    • Function
      Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
    • Tissue specificity
      Plasma.
    • Involvement in disease
      Defects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
    • Sequence similarities
      Contains 1 CTCK (C-terminal cystine knot-like) domain.
      Contains 4 TIL (trypsin inhibitory-like) domains.
      Contains 3 VWFA domains.
      Contains 3 VWFC domains.
      Contains 4 VWFD domains.
    • Domain
      The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
    • Post-translational
      modifications
      All cysteine residues are involved in intrachain or interchain disulfide bonds.
      N- and O-glycosylated.
    • Cellular localization
      Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
    • Information by UniProt
    • Database links
    • Alternative names
      • Coagulation factor VIII antibody
      • Coagulation factor VIII VWF antibody
      • F8VWF antibody
      • Factor VIII related antigen antibody
      • von Willebrand antigen 2 antibody
      • von Willebrand antigen II antibody
      • Von Willebrand disease antibody
      • VWD antibody
      • vWF antibody
      • VWF_HUMAN antibody
      see all

    Images

    • All lanes : Anti-Von Willebrand Factor antibody [EPR12011] (ab174290) at 1/1000 dilution

      Lane 1 : Human serum lysate
      Lane 2 : Human plasma lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 309 kDa

    References

    This product has been referenced in:
    • Luo X  et al. Caveolin 1-related autophagy initiated by aldosterone-induced oxidation promotes liver sinusoidal endothelial cells defenestration. Redox Biol 13:508-521 (2017). Read more (PubMed: 28734243) »

    See 1 Publication for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab174290.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up